FK506-binding protein 12 (FKBP12) (FKBP12)

FK506-binding protein 12 (FKBP12), encoded by the FKBP1A gene, is a ubiquitous cytosolic protein belonging to the immunophilin family that possesses peptidyl-prolyl cis-trans isomerase (PPIase) activity [1]. While it naturally functions in protein folding and the regulation of calcium release channels like the ryanodine receptor, it is best known as the intracellular receptor for the immunosuppressant drug tacrolimus (FK506) [2, 3]. Upon binding tacrolimus, FKBP12 forms a gain-of-function complex that specifically targets and inhibits calcineurin, a calcium-dependent serine/threonine phosphatase [4]. This inhibition prevents the dephosphorylation of the Nuclear Factor of Activated T-cells (NFAT), thereby blocking its translocation to the nucleus and the subsequent transcription of interleukin-2 (IL-2) and other cytokines necessary for T-cell activation [2, 4]. This mechanism is fundamental in suppressing T-cell-mediated immune responses, making it a cornerstone in preventing organ transplant rejection and managing autoimmune disorders [5]. However, the broad expression of calcineurin leads to significant side effects, most notably nephrotoxicity and neurotoxicity, which require careful therapeutic drug monitoring [2, 5].

Other names

FKBP1AFKBP-12FKBP1Peptidyl-prolyl cis-trans isomerase FKBP1APPIase FKBP1ARotamase12 kDa FK506-binding protein

Tacrolimus binds to FKBP12 to form a drug-protein complex that specifically inhibits the phosphatase activity of calcineurin. This inhibition prevents the dephosphorylation of the transcription factor NFAT (Nuclear Factor of Activated T-cells), thereby blocking its nuclear translocation and the subsequent transcription of interleukin-2 (IL-2) and other cytokines essential for T-cell activation [2, 4].